Pathos AI raises $237 million at reported $3 billion valuation
Bristol Myers Squibb led Pathos AI’s Series E. The round was smaller than its 2025 financing, while its reported post-money valuation was higher.
Bristol Myers Squibb led Pathos AI’s Series E. The round was smaller than its 2025 financing, while its reported post-money valuation was higher.
Tenstorrent closed a $1.5 billion Series E at a $6.2 billion post-money valuation. It plans to scale Galaxy server deployment and advance AI and CPU intellectual property it licenses to customers designing their own chips.